Literature DB >> 22454955

The persistence of adriamycin in man and rat.

P M Wilkinson1, G E Mawer.   

Abstract

1 Adriamycin was administered as a single intravenous dose. The plasma concentration in man and rat decayed as a double exponential function of time. 2 A two compartment model was used to predict plasma and tissue concentrations in man and the rat. The validity of the tissue concentration predictions was confirmed experimentally in the rat. 3 Tissue components had a high capacity for the drug. There was evidence in the rat of preferential accumulation in the liver, spleen and bone marrow. 4 The large tissue capacity and the prolonged half time for elimination predispose to accumulation. This may be responsible for the greater toxicity of treatment schedules with short intervals between consecutive doses.

Entities:  

Year:  1974        PMID: 22454955      PMCID: PMC1402555          DOI: 10.1111/j.1365-2125.1974.tb00244.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Distribution of tritiated daunomycin in man by a simplified method.

Authors:  G Di Fronzo; G Bonadonna
Journal:  Rev Eur Etud Clin Biol       Date:  1970-03

2.  Analysis of the pharmacokinetic characteristics, pharmacological and chemotherapeutic activity of 14-Hydroxy-daunomycin (Adriamycin), a new drug endowed with an antitumour activity.

Authors:  E Arena; N D'Alessandro; L Dusonchet; N Gebbia; F Gerbasi; M Palazzoadriano; A Raineri; L Rausa; E Tubaro
Journal:  Arzneimittelforschung       Date:  1971-08

3.  The synthesis of [1,2-3H]vitamin D3 and the tissue localization of a 0.25-mu-g (10 IU) dose per rat.

Authors:  P F Neville; H F DeLuca
Journal:  Biochemistry       Date:  1966-07       Impact factor: 3.162

4.  Pharmacokinetics and metabolism of adriamycin in man.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Daunomycin and adriamycin metabolism via reductive glycosidic cleavage.

Authors:  M A Asbell; E Schwartzbach; F J Bullock; D W Yesair
Journal:  J Pharmacol Exp Ther       Date:  1972-07       Impact factor: 4.030

6.  Distribution and metabolism of adriamycin in mice. Comparison with daunomycin.

Authors:  G Di Fronzo; R A Gambetta; L Lenaz
Journal:  Rev Eur Etud Clin Biol       Date:  1971 Jun-Jul

7.  Interaction of some daunomycin derivatives with deoxyribonucleic acid and their biological activity.

Authors:  A Di Marco; F Zunino; R Silverstrini; C Gambarucci; R A Gambetta
Journal:  Biochem Pharmacol       Date:  1971-06       Impact factor: 5.858

8.  Shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment.

Authors:  S Riegelman; J C Loo; M Rowland
Journal:  J Pharm Sci       Date:  1968-01       Impact factor: 3.534

9.  Distribution of tritiated daunomycin (NSC-82151) in normal rats.

Authors:  A Rusconi; G Di Fronzo; A Di Marco
Journal:  Cancer Chemother Rep       Date:  1968-04

10.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods.

Authors:  N R Bachur; A L Moore; J G Bernstein; A Liu
Journal:  Cancer Chemother Rep       Date:  1970-04
View more
  9 in total

1.  Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer.

Authors:  M H Bronchud; J M Margison; A Howell; M Lind; S B Lucas; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Comparative metabolism and excretion of adriamycin in man, monkey, and rat.

Authors:  P M Wilkinson; M Israel; W J Pegg; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Microfluidic technique to measure intratumoral transport and calculate drug efficacy shows that binding is essential for doxorubicin and release hampers Doxil.

Authors:  Bhushan J Toley; Zachary G Tropeano Lovatt; Josephine L Harrington; Neil S Forbes
Journal:  Integr Biol (Camb)       Date:  2013-09       Impact factor: 2.192

4.  Disposition of 14C-labelled 4'-epidoxorubicin and doxorubicin in the rat. A comparative study.

Authors:  F Arcamone; M Lazzati; G P Vicario; G Zini
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Preclinical pharmacology of the anthrapyrazole analog oxantrazole (NSC-349174, piroxantrone).

Authors:  S K Frank; D A Mathiesen; M Szurszewski; M J Kuffel; M M Ames
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

6.  Effect of cyclophosphamide pretreatment on the short-term disposition and biliary excretion of adriamycin metabolites in rat.

Authors:  N Hartman; P J Basseches; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1982-12       Impact factor: 3.333

7.  Time dependency of adriamycin and adriamycinol kinetics.

Authors:  P Gil; R Favre; A Durand; A Iliadis; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

8.  Cytofluorescence localization of adriamycin in the nervous system. I. Distribution of the drug in the central nervous system of normal adult mice after intravenous injection.

Authors:  L Bigotte; B Arvidson; Y Olsson
Journal:  Acta Neuropathol       Date:  1982       Impact factor: 17.088

9.  Cardiac spheroids as promising in vitro models to study the human heart microenvironment.

Authors:  Liudmila Polonchuk; Mamta Chabria; Laura Badi; Jean-Christophe Hoflack; Gemma Figtree; Michael J Davies; Carmine Gentile
Journal:  Sci Rep       Date:  2017-08-01       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.